Why the Fisher & Paykel Healthcare (ASX:FPH) share price is sinking 6% today

This healthcare share is having a bad day…

| More on:
A man wearing a white coat and glasses is wide-mouthed in surprise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Fisher & Paykel Healthcare's shares are sinking on Wednesday morning
  • Investors have responded negatively to its sales guidance update for FY 2022
  • Fisher & Paykel Healthcare also warned that freight costs are hurting margins

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is under pressure on Wednesday.

In morning trade, the medical device company's shares are down 6% to $24.20.

Why is the Fisher & Paykel Healthcare share price sinking?

Investors have been selling down the Fisher & Paykel Healthcare share price this morning following the release of a trading update out of the company.

According to the release, with the end of its financial year rapidly approaching, management now has a good idea of the revenue it will generate in FY 2022.

Based on current exchange rates, Fisher & Paykel Healthcare expects full year operating revenue for the 12 months ending 31 March to be in the range of NZ$1.675 billion to NZ$1.70 billion.

This represents a 13.7% to 15% decline year on year from NZ$1.97 billion in FY 2021.

Based on this, there has been a marked softening of its performance during the second half, as Fisher & Paykel Healthcare's half year operating revenue was only down 2% over the prior corresponding period.

What's happening?

Management explained that its performance has been impacted by softening demand in the hospital consumables segment due to the Omicron variant causing lower respiratory intervention requirements and a mild flu season in the Northern Hemisphere.

Fisher & Paykel Healthcare's Managing Director and Chief Executive Officer, Lewis Gradon, said: "Our second half hospital consumables revenue is currently tracking to be similar to the hospital consumables revenue that we reported in the first half of the 2022 financial year. This is consistent with reports of the increasing prevalence of the Omicron variant over the last two months and its associated lower respiratory intervention requirements, as well as a relatively mild flu season in the Northern Hemisphere."

"In our Homecare product group, growth in sales of our OSA masks is currently tracking above our first half growth rate despite supply constraints of treatment hardware in the market," he added.

Also putting pressure on the Fisher & Paykel Healthcare share price is news that its margins have been impacted by higher freight costs.

Mr Gradon said: "Freight rates remain elevated and for the 2022 financial year are expected to impact our long-term gross margin target of 65% by approximately 250 basis points."

Nevertheless, the Chief Executive Officer remains positive on the long term future of the company.

He concluded: "Regardless of how COVID-19 effects unfold over the short term, we are confident our business is well-placed to contribute to a positive change in clinical practice and improving outcomes for respiratory patients in general over the long term."

Should you invest $1,000 in Fisher & Paykel Healthcare Corporation Limited right now?

Before you buy Fisher & Paykel Healthcare Corporation Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Fisher & Paykel Healthcare Corporation Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

How are Cochlear shares impacted by Trump's tariffs?

Will the company escape from the tariffs? Let's find out.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

3 reasons to buy this surging ASX All Ords healthcare share today

A top expert forecasts more outperformance from this rocketing ASX healthcare stock.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Down 11% in 2025, are CSL shares a good buy right now?

Are CSL shares likely to go up from here?

Read more »

Three healthcare workers look and point at at medical image
Healthcare Shares

Pro Medicus to buyback 10.4 million shares. What does this mean?

Is this a sign to buy?

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Why I think this ASX small-cap stock is a bargain at 40 cents

Here’s why this business has a compelling outlook...

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

One likely reason the market has soured on Pro Medicus

Is there opportunity for brave investors?

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Hedge the rise in your health insurance premium with these 2 ASX stocks

Sick of price rises? Get on the other side of the transaction.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

2 ASX 200 biotech stocks announcing big news today

Let's see how the market has responded to these announcements.

Read more »